High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: Predictors of complete remission

Bone Marrow Transplantation

Volumn 33, Issue 1, 2004, Pages 61-64

  Nadal, E ^a   Gine E ^a   Blade J ^a   Esteve, J ^a   Rosinol L ^a   Fernandez Aviles F ^a   Marin, P ^a   Martinez, C ^a   Rovira, M ^a   Urbano, A ^a   Carreras, E ^a   Montserrat, E ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

High dose therapy; Multiple myeloma; Stem cell transplantation and complete remission

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; M PROTEIN; MELPHALAN; METHOTREXATE; PREDNISONE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SENSITIVITY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; SEROLOGY; SURVIVAL RATE; SURVIVAL TIME; URINALYSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0742324364     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704313     Document Type: Article

References (21)

1. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842.
2. Bladé J, San Miguel JF, Fontanillas M et al. Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients. Hematol J 2001; 2: 272-278.
3. Attal M, Harousseau JL, Stoppa AM et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
4. Child JA, Morgan GJ, Davies FE et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
5. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
6. Lenhoff S, Hjort M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem-cell support in patients younger than 60 years with newly diagnosed multiple myeloma. Blood 2000; 95: 7-11.
7. Palumbo A, Triolo S, Argentino C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248-1253.
8. Fermand JP, Ravaud P, Katsahian S et al. High dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients 55 to 65 years of age. Blood 1999; 94 (Suppl 1): 396a.
9. Segeren CM, Sonneveld P, van der Holt B et al. Dutch-Belgian Hemato-Oncology Cooperative Study Group. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144-2151.
10. Alexanian R, Dimopoulos MA, Hester J et al. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278-4282.
11. Bladé J, San Miguel J, Fontanillas M et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation who were conventionally treated. J Clin Oncol 1996; 94: 2167-2173.
12. Alexanian R, Weber D, Giralt S et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043.
13. Bladé J, Esteve J, Rives S et al. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845-849.
14. Chronic Leukaemia-Myeloma Task Force. National Cancer Institute: proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973; 4: 145-158.
15. Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
16. Blade J, San Miguel JF, Alcala A et al. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 1993; 11: 1165-1171.
17. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-89.
18. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and haemopoetic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
19. Peto R, Pike MC. Conservatism of the approximation sigma (O-E)2-E in the log rank test for survival data or tumor incidence data. Biometrics 1973; 29: 579-584.
20. Lahuerta J, Martínez-Lopez J, de la Serna J et al. Remission status defined by immunofixation vs electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438-446.
21. Vesole DH, Barlogie B, Jagannath S et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-956.